# CureGN

> **NIH NIH U24** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2021 · $150,000

## Abstract

ABSTRACT
Cure Glomerulonephropathy (CureGN) is a National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK)-sponsored, multi-center international consortium established in 2013 to study the natural
history of glomerular diseases (minimal change disease, focal segmental glomerulosclerosis, membranous
nephropathy, and IgA nephropathy), understand their underlying biology, develop biomarkers to resolve
disease heterogeneity, and ultimately improve therapeutic options. CureGN has made progress in: 1)
establishing a large, ethnically diverse longitudinal observational cohort of glomerular disease patients; 2)
creating a rich, well-curated clinical data set and linked biospecimens; 3) establishing the largest repository of
digital kidney biopsies; and 4) an infrastructure that will facilitate translational and clinical research by core and
ancillary study scientists.
Defining the genetic and genomic landscape of the diseases studied by CureGN has been a core aim from the
initiation of the study and the emerging genetic information of CureGN participants is currently utilized by a
multitude of core and ancillary studies.
As CureGN will continue to recruit a limited set of patients, the blood biospecimens from the enrollemtn visit
will need to be processed so that isolated DNA and RNA can be submitted to the NIDDK central biorepository
for use by the scientific community.
This supplemental funding request asked to cover the isolation costs for up to 1000 patients (200 patients
already recruited, and up to 800 to be recruited depending on the recruit to replace needs of CureGN 2).
CureGN will use a centralized service by Precision for Medicine who has an outstanding track record for
processing excellence and quality control metrics in place. This service provider will also be able to access the
biosamples from the incoming CureGN shipments to the NIDDK CBR, reducing sample transfer logistical
burden and opportunity for sample losses substantially.

## Key facts

- **NIH application ID:** 10467441
- **Project number:** 3U24DK100845-09S3
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** BRENDA W GILLESPIE
- **Activity code:** U24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $150,000
- **Award type:** 3
- **Project period:** 2021-08-23 → 2024-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10467441

## Citation

> US National Institutes of Health, RePORTER application 10467441, CureGN (3U24DK100845-09S3). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10467441. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*